11110081

Veloxis Pharmaceuticals AS v. Zydus Cadila et al.

Open

Docket:: 1:26-cv-00467
Court:: Delaware District Court
Forum:: District Court
Filed:: 2026-04-23
Cause:: Infringement
Industry:: Medical (M)

Patents:11419823 10864199 8685998 8664239 11123331 12403095 10166190 11110081 12083103 9549918

π Veloxis Pharmaceuticals AS Δ Zydus Cadila Δ Zydus Lifesciences Ltd

Infringed product

The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.

Veloxis Pharmaceuticals AS v. Intas Pharmaceuticals Ltd. et al.

judgment

Docket:: 1:22-cv-00909
Court:: Delaware District Court
Filed:: 2022-07-07
Terminated:: 2024-01-24

Patents:11110081

π Veloxis Pharmaceuticals AS Δ Intas Pharmaceuticals Ltd.Δ Accord Healthcare Inc.

The case involved patent infringement concerning tacrolimus drug products. A consent judgment resulted in a permanent injunction for Veloxis Pharmaceuticals, Inc.

Veloxis Pharmaceuticals AS v. Alkem Laboratories Ltd.

Open

Docket:: 1:24-cv-00784
Court:: Delaware District Court
Filed:: 2024-07-03

Patents:11110081

π Veloxis Pharmaceuticals AS Δ Alkem Laboratories Ltd.

This is an infringement case. Alkem Laboratories Ltd. admitted sending a Notice of Paragraph IV Certification regarding its ANDA for tacrolimus extended-release tablets, citing US Patent 11110081 among others.

Veloxis Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd. et al.

Open

Docket:: 1:24-cv-00726
Court:: Delaware District Court
Filed:: 2024-06-19

Patents:11110081

π Veloxis Pharmaceuticals, Inc.Δ Sun Pharmaceutical Industries Ltd.Δ Sun Pharmaceutical Industries, Inc.

Veloxis Pharmaceuticals, Inc. filed this action asserting several patents, including US Patent 11110081. The thirty-month stay deadline for this case is November 9, 2026.

Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., USA

Open

Docket:: 1:25-cv-00458
Court:: Delaware District Court
Filed:: 2025-04-14

Patents:11110081

π Veloxis Pharmaceuticals, Inc.Δ Glenmark Pharmaceuticals Inc., USA

This case asserts infringement of US Patent 11110081, among others, relating to Glenmark's ANDA for tacrolimus extended-release tablets. A stipulation and order regarding a stay was filed on February 2, 2026.